new glp 1 drug retatrutide Promises Big Weight Loss, but Safety Remains a Question Back in 2023 we saw

Soft tissue facial changes following massive weight loss secondary to medical and surgical bariatric interventions: a systematic review

Clinical trials show that some users lost 15% or more of their body weight

About one in seven adults who have ever used GLP-1 medications say they are no longer using these drugs because of the cost (14%), similar to the share who report no longer taking the medications because of side effects (13%)

[On-screen text: We can make other recommendations to help with your weight-loss journey, too.] [Cut to a woman checking out at pharmacy register.] Alex, speaking: We sell a lot of unique products at CVS

References Ai X, Yu P, Peng L, et al

States will announce participation decisions in mid-2026